vimarsana.com

Latest Breaking News On - Parkman healthcare partners - Page 5 : vimarsana.com

Wedbush Raises Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target to $34.00

Wedbush Raises Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target to $34.00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird
Denali-advisors
Asset-management-inc
Cantor-fitzgerald
News-ratings-for-longboard-pharmaceuticals-daily
Citigroup
Longboard-pharmaceuticals-inc
Analyst-recommendations-for-longboard-pharmaceuticals
Jennison-associates
Longboard-pharmaceuticals
Platinum-investment-management-ltd

RxSight, Inc. (NASDAQ:RXST) CEO Sells $2,406,000.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CEO Sells $2,406,000.00 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Stifel-nicolaus
Needham-company
Vanguard-group-inc
Rxsight-inc
Jpmorgan-chase-co
Parkman-healthcare-partners
Artisan-partners-limited-partnership
Lord-abbett
Nasdaq
Victory-capital-management-inc
Rxsight-company-profile

Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells 3,152 Shares of Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) CEO Kevin Koch sold 3,152 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $59,604.32. Following the sale, the chief executive officer now directly owns 14,478 shares in the […]

Canada
Kevin-koch
Piper-sandler
Frazier-life-sciences-management
Parkman-healthcare-partners
Sectoral-asset-management-inc
Royal-bank
Vontobel-holding-ltd
Edgewise-therapeutics-inc
Nasdaq
Securities-exchange-commission
Perceptive-advisors

Cantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the company’s current price. Other […]

Robertw-baird
Longboard-pharmaceuticals-stock-performance
Longboard-pharmaceuticals
Parkman-healthcare-partners
Longboard-pharmaceuticals-company-profile
Td-asset-management-inc
Cantor-fitzgerald
Analyst-recommendations-for-longboard-pharmaceuticals
Bourgeon-capital-management
News-ratings-for-longboard-pharmaceuticals-daily
Denali-advisors

Cantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $60.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the stock’s current […]

Robertw-baird
Longboard-pharmaceuticals-company-profile
Td-asset-management-inc
Cantor-fitzgerald
Longboard-pharmaceuticals-stock-performance
Parkman-healthcare-partners
Longboard-pharmaceuticals
Jennison-associates
News-ratings-for-longboard-pharmaceuticals-daily
Longboard-pharmaceuticals-inc
Citigroup

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.